Severe hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: A case report and review of the literature

Onkologie

Volumn 30, Issue 12, 2007, Pages 651-654

  Brodmanna, Stefan ^a   Klaas, Evelyne Gyr ^a   Cathomas, Richard ^a   Girardi, Vincenzo ^b   Von Moos, Roger ^a  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^b CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

Author keywords

Antineoplastic agents; Bortezomib; Hyponatremia; Mantle cell lymphoma; Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE BESYLATE; BORTEZOMIB; POTASSIUM CHLORIDE; SODIUM CHLORIDE;

AGED; ARTICLE; ATAXIA; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FEMALE; FLUID INTAKE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY FUNCTION; LABORATORY TEST; LYMPHADENOPATHY; MANTLE CELL LYMPHOMA; NEUROLOGIC EXAMINATION; SLURRED SPEECH; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 37049039708     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109979     Document Type: Article

References (51)

1. Sorensen JB, Andersen MK, Hansen HH: Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238:97-110.
2. Kumar S, Berl T: Sodium. Lancet 1998;352:220-228.
3. Adrogue HJ, Madias NE: Hyponatremia. N Engl J Med 2000;342:1581-1589.
4. Gillessen S, Groettup M, Cerny T: The proteasome, a new target for cancer therapy. Onkologie 2002;25:534-539.
5. Ludwig H, Khayat D, Giaccone G, Facon T: Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005;104:1794-1807.
6. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172.
7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
9. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA: A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116-121.
10. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874.
11. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675.
12. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
13. Bondy PK, Gilby ED: Endocrine function in small cell undifferentiated carcinoma of the lung. Cancer 1982;50:2147-2153.
14. Maurer LH, O'Donnell JF, Kennedy S, Faulkner CS, Rist K, North WG: Human neurophysins in carcinoma of the lung: relation to histology, disease stage, response rate, survival, and syndrome of inappropriate antidiuretic hormone secretion. Cancer Treat Rep 1983;67:971-976.
15. Talmi YP, Hoffman HT, McCabe BF: Syndrome of inappropriate secretion of arginine vasopressin in patients with cancer of the head and neck. Ann Otol Rhinol Laryngol 1992;101:946-949.
16. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL: Phase I trial of the proteasome inhibitor ps-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427.
17. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA: Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1400-1412.
18. Arzneimittelkompendium der Schweiz®, Documed AG, Basel, Switzerland, 2007: http://www.kompendium.ch, accessed March 2007.
19. Product information Doxil®, Tibotec Therapeutics, Raritan, N.J., USA. Revised May 2006: http://www.doxil.com, accessed April 6, 2007.
20. Diskin C, Dansby LM, Radcliff L, Carter TB, Graves E, Graves A: Recurrent hyponatremia after intrathecal methotrexate not related to antidiuretic hormone: is a natriuretic peptide activated? Am J Med Sci 2006;331:37-39.
21. Lei KI, Wickham NW, Johnson PJ: Severe hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone in a patient receiving interferon-alpha for chronic myeloid leukemia. Am J Hematol 1995;49:100.
22. Tscherning C, Rubie H, Chancholle A, Claeyssens S, Robert A, Fabre J, Bouissou F: Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 1994;73:1761-1763.
23. Antony A, Robinson WA, Roy C, Pelander W, Donohue R: Inappropriate antidiuretic hormone secretion after high dose vinblastine. J Urol 1980;123:783-784.
24. Ginsberg SJ, Comis RL, Fitzpatrick AV: Vinblastine and inappropriate ADH secretion. N Engl J Med 1977;296:941.
25. Stahel RA, Oelz O: Syndrome of inappropriate ADH secretion secondary to vinblastine. Cancer Chemother Pharmacol 1982;8:253-254.
26. Zavagli G, Ricci G, Tataranni G, Mapelli G, Abbasciano V: Life-threatening hyponatremia caused by vinblastine. Med Oncol Tumor Pharmacother 1988;5:67-69.
27. Berghmans T: Hyponatremia related to medical anticancer treatment. Support Care Cancer 1996;4:341-350.
28. McCarron M, Wright GD, Roberts SD: Water intoxication after low dose cyclophosphamide. BMJ 1995;311:292.
29. Salido M, Macarron P, Hernandez-Garcia C, D'Cruz DP, Khamashta MA, Hughes GR: Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus 2003;12:636-639.
30. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654.
31. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X, Chang AY: Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-3576.
32. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587.
33. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
34. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
35. Stopeck AT, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher RI, Miller TP: Phase II trial of single agent bevacizumab (avastin) in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group study S0108. ASCO Annu Meet Proc, J Clin Oncol 2005;23:6592.
36. Ritch PS: Cis-dichlorodiammineplatinum II-induced syndrome of inappropriate secretion of antidiuretic hormone. Cancer 1988;61:448-450.
37. Vassal G, Rubie H, Kalifa C, Hartmann O, Lemerle J: Hyponatremia and renal sodium wasting in patients receiving cisplatinum. Pediatr Hematol Oncol 1987;4:337-344.
38. Harlow PJ, DeClerck YA, Shore NA, Ortega JA, Carranza A, Heuser E: A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer 1979;44:896-898.
39. Cantwell BM, Idle M, Millward MJ, Hall G, Lind MJ: Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion. Ann Oncol 1990;1:232.
40. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA: A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005;90:157-163.
41. Tiffany NM, Wersinger EM, Garzotto M, Beer TM: Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology 2004;63:934-939.
42. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006;12:4899-4907.
43. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA: Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-2011.
44. Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH: Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 2007;25:362-369.
45. Greenbaum-Lefkoe B, Rosenstock JG, Belasco JB, Rohrbaugh TM, Meadows AT: Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan. Cancer 1985;55:44-46.
46. Jost LM: Overdose with melphalan (Alkeran): symptoms and treatment. A review (article in German). Onkologie 1990;13:96-101.
47. Liu B, Barrett T, Choyke P, Maynard K, Wright J, Kummar S, Murgo A, Doroshow J, Gutierrez M, Group NB-W: A phase II study of BAY 43-9006 (sorafenib) in patients with relapsed non-small-cell lung cancer (NSCLC). ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2006;24:17119.
48. Sica S, Cicconi S, Sora F, Chiusolo P, Piccirillo N, Laurenti L, La Barbera EO, Giordano G, Leone G: Inappropriate antidiuretic hormone secretion after high-dose thiotepa. Bone Marrow Transplant 1999;24:571-572.
49. Hammond IW, Ferguson JA, Kwong K, Muniz E, Delisle F: Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of vincristine: an over-representation of Asians? Pharmacoepidemiol Drug Saf 2002;11:229-234.
50. Stuart MJ, Cuaso C, Miller M, Oski FA: Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. Blood 1975;45:315-320.
51. Whittaker JA, Parry DH, Bunch C, Weatherall DJ: Coma associated with vincristine therapy. Br Med J 1973;4:335-337.